|
1
|
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.
|
J Am Coll Cardiol
|
2007
|
10.19
|
|
2
|
Prevalence of conventional risk factors in patients with coronary heart disease.
|
JAMA
|
2003
|
6.84
|
|
3
|
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.
|
Circulation
|
2007
|
6.78
|
|
4
|
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
|
JAMA
|
2008
|
6.55
|
|
5
|
Bivalirudin for patients with acute coronary syndromes.
|
N Engl J Med
|
2006
|
5.49
|
|
6
|
2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons.
|
J Am Coll Cardiol
|
2011
|
3.37
|
|
7
|
Intravenous platelet blockade with cangrelor during PCI.
|
N Engl J Med
|
2009
|
3.31
|
|
8
|
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
|
N Engl J Med
|
2011
|
3.20
|
|
9
|
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
|
JAMA
|
2008
|
3.09
|
|
10
|
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
|
JAMA
|
2007
|
3.07
|
|
11
|
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
|
J Am Coll Cardiol
|
2004
|
2.97
|
|
12
|
2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
|
Circulation
|
2012
|
2.88
|
|
13
|
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
|
Circulation
|
2011
|
2.72
|
|
14
|
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
|
Lancet
|
2007
|
2.67
|
|
15
|
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
|
Lancet
|
2009
|
2.62
|
|
16
|
Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
|
Chest
|
2008
|
2.56
|
|
17
|
2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
|
J Am Coll Cardiol
|
2012
|
2.52
|
|
18
|
Platelet inhibition with cangrelor in patients undergoing PCI.
|
N Engl J Med
|
2009
|
2.52
|
|
19
|
Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
|
Chest
|
2012
|
2.50
|
|
20
|
Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial.
|
Circulation
|
2009
|
2.47
|
|
21
|
2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
|
Circulation
|
2011
|
2.45
|
|
22
|
2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
|
J Am Coll Cardiol
|
2011
|
2.37
|
|
23
|
Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial.
|
J Am Coll Cardiol
|
2007
|
2.14
|
|
24
|
Enhanced prediction of mortality after percutaneous coronary intervention by consideration of general and neurological indicators.
|
JACC Cardiovasc Interv
|
2011
|
2.01
|
|
25
|
A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study.
|
J Thorac Cardiovasc Surg
|
2006
|
2.00
|
|
26
|
Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial.
|
Circulation
|
2009
|
1.88
|
|
27
|
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
|
J Am Coll Cardiol
|
2009
|
1.86
|
|
28
|
Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
|
JAMA
|
2007
|
1.84
|
|
29
|
2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
|
Circulation
|
2013
|
1.81
|
|
30
|
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.
|
Circulation
|
2009
|
1.77
|
|
31
|
2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
|
J Am Coll Cardiol
|
2013
|
1.76
|
|
32
|
Poverty, process of care, and outcome in acute coronary syndromes.
|
J Am Coll Cardiol
|
2003
|
1.71
|
|
33
|
Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
J Am Coll Cardiol
|
2009
|
1.70
|
|
34
|
Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
|
J Interv Cardiol
|
2009
|
1.64
|
|
35
|
Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial.
|
Am J Cardiol
|
2007
|
1.59
|
|
36
|
Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial.
|
Ann Thorac Surg
|
2007
|
1.53
|
|
37
|
Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies.
|
Ann Thorac Surg
|
2007
|
1.52
|
|
38
|
Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model.
|
Arterioscler Thromb Vasc Biol
|
2003
|
1.52
|
|
39
|
Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
J Am Coll Cardiol
|
2008
|
1.52
|
|
40
|
Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.
|
JACC Cardiovasc Interv
|
2011
|
1.50
|
|
41
|
Cause of death within 30 days of percutaneous coronary intervention in an era of mandatory outcome reporting.
|
J Am Coll Cardiol
|
2013
|
1.48
|
|
42
|
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
|
Am Heart J
|
2011
|
1.47
|
|
43
|
Magnitude and consequences of missing the acute infarct-related circumflex artery.
|
Am Heart J
|
2009
|
1.42
|
|
44
|
Clinical outcomes of drug-eluting versus bare-metal in-stent restenosis.
|
Catheter Cardiovasc Interv
|
2010
|
1.41
|
|
45
|
Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia.
|
JACC Cardiovasc Interv
|
2009
|
1.40
|
|
46
|
Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials.
|
Catheter Cardiovasc Interv
|
2002
|
1.39
|
|
47
|
Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center.
|
Am J Cardiol
|
2005
|
1.39
|
|
48
|
Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury.
|
Circulation
|
2003
|
1.38
|
|
49
|
Acute pharmacological conversion of atrial fibrillation to sinus rhythm: is short-term symptomatic therapy worth it? A report from the December 2007 Meeting of the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration.
|
Circulation
|
2008
|
1.37
|
|
50
|
Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach.
|
Eur Heart J
|
2007
|
1.37
|
|
51
|
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes.
|
J Am Coll Cardiol
|
2006
|
1.37
|
|
52
|
Sharing Data from Cardiovascular Clinical Trials - A Proposal.
|
N Engl J Med
|
2016
|
1.34
|
|
53
|
Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?
|
Circulation
|
2002
|
1.30
|
|
54
|
Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.
|
JACC Cardiovasc Interv
|
2011
|
1.26
|
|
55
|
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
|
Am Heart J
|
2009
|
1.24
|
|
56
|
The role of spironolactone in the treatment of patients with refractory hypertension.
|
Am J Hypertens
|
2002
|
1.24
|
|
57
|
Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox).
|
Am J Cardiol
|
2002
|
1.19
|
|
58
|
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
|
Am Heart J
|
2004
|
1.19
|
|
59
|
In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis.
|
Arch Intern Med
|
2003
|
1.17
|
|
60
|
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
|
J Am Coll Cardiol
|
2009
|
1.16
|
|
61
|
Drug-eluting stent fracture and acute coronary syndrome.
|
Cardiovasc Revasc Med
|
2009
|
1.14
|
|
62
|
The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials.
|
J Am Coll Cardiol
|
2006
|
1.09
|
|
63
|
Stent-assisted detachable coil embolization of pseudoaneurysms in the coronary circulation.
|
Catheter Cardiovasc Interv
|
2006
|
1.08
|
|
64
|
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial.
|
Circulation
|
2002
|
1.06
|
|
65
|
Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
|
Chest
|
2008
|
1.05
|
|
66
|
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
|
Eur Heart J
|
2012
|
1.02
|
|
67
|
Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: results of a pilot study.
|
J Thorac Cardiovasc Surg
|
2005
|
1.01
|
|
68
|
Is clopidogrel cardiovascular medicine's double-edged sword?
|
Circulation
|
2006
|
1.01
|
|
69
|
A rare complication of infective endocarditis.
|
Cleve Clin J Med
|
2010
|
1.00
|
|
70
|
Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization.
|
Catheter Cardiovasc Interv
|
2004
|
0.99
|
|
71
|
Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study.
|
J Thorac Cardiovasc Surg
|
2006
|
0.99
|
|
72
|
Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients < or =40 years old.
|
Am J Cardiol
|
2003
|
0.98
|
|
73
|
Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V.
|
Arch Intern Med
|
2007
|
0.98
|
|
74
|
Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model.
|
J Pharmacol Exp Ther
|
2005
|
0.98
|
|
75
|
Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
|
Am J Cardiovasc Drugs
|
2010
|
0.96
|
|
76
|
Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model.
|
J Cardiovasc Pharmacol
|
2005
|
0.95
|
|
77
|
Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model.
|
Mol Ther
|
2003
|
0.95
|
|
78
|
Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification.
|
JAMA
|
2003
|
0.95
|
|
79
|
Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
|
J Am Coll Cardiol
|
2008
|
0.94
|
|
80
|
ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy).
|
Am J Cardiol
|
2004
|
0.92
|
|
81
|
Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
J Am Coll Cardiol
|
2008
|
0.92
|
|
82
|
Platelet, not endothelial, P-selectin is required for neointimal formation after vascular injury.
|
Arterioscler Thromb Vasc Biol
|
2005
|
0.91
|
|
83
|
Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.
|
J Am Coll Cardiol
|
2003
|
0.90
|
|
84
|
Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes.
|
Am J Cardiol
|
2003
|
0.90
|
|
85
|
Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.
|
Am J Med
|
2002
|
0.90
|
|
86
|
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
|
Circulation
|
2004
|
0.90
|
|
87
|
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
|
Am J Cardiol
|
2005
|
0.88
|
|
88
|
Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force.
|
Catheter Cardiovasc Interv
|
2007
|
0.88
|
|
89
|
Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward.
|
Circ Cardiovasc Qual Outcomes
|
2012
|
0.86
|
|
90
|
Local delivery of nitric oxide from an eluting stent to inhibit neointimal thickening in a porcine coronary injury model.
|
Yonsei Med J
|
2002
|
0.86
|
|
91
|
Final results of the ReoPro readministration registry.
|
Am J Cardiol
|
2004
|
0.85
|
|
92
|
Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial.
|
J Thromb Thrombolysis
|
2011
|
0.85
|
|
93
|
Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting.
|
Am J Cardiol
|
2004
|
0.85
|
|
94
|
Managing adverse effects and drug-drug interactions of antiplatelet agents.
|
Nat Rev Cardiol
|
2011
|
0.84
|
|
95
|
Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).
|
Am J Cardiol
|
2005
|
0.84
|
|
96
|
Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial.
|
J Am Coll Cardiol
|
2005
|
0.84
|
|
97
|
Use of ticlopidine and cilostazol after intracoronary drug-eluting stent placement in a patient with previous clopidogrel-induced thrombotic thrombocytopenic purpura: a case report.
|
J Invasive Cardiol
|
2006
|
0.84
|
|
98
|
Impact of female sex on outcome after percutaneous coronary intervention.
|
Am Heart J
|
2004
|
0.84
|
|
99
|
The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial.
|
Am Heart J
|
2005
|
0.84
|
|
100
|
Management of the patient with diabetes and coronary artery disease: a contemporary review.
|
Future Cardiol
|
2013
|
0.84
|
|
101
|
Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
|
Circ Cardiovasc Interv
|
2012
|
0.83
|
|
102
|
The role of clopidogrel in the management of ischemic heart disease.
|
Curr Opin Cardiol
|
2007
|
0.83
|
|
103
|
Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial.
|
Eur Heart J
|
2006
|
0.82
|
|
104
|
Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusion.
|
Thromb Haemost
|
2002
|
0.82
|
|
105
|
Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
|
Cleve Clin J Med
|
2009
|
0.82
|
|
106
|
Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis.
|
J Cardiovasc Pharmacol Ther
|
2005
|
0.82
|
|
107
|
Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes.
|
Am J Cardiol
|
2005
|
0.82
|
|
108
|
Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade.
|
Catheter Cardiovasc Interv
|
2005
|
0.82
|
|
109
|
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
|
J Am Coll Cardiol
|
2004
|
0.81
|
|
110
|
Predictive models for short- and long-term adverse outcomes following discharge in a contemporary population with acute coronary syndromes.
|
Am J Cardiovasc Dis
|
2013
|
0.81
|
|
111
|
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
|
BMC Nephrol
|
2014
|
0.81
|
|
112
|
Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
|
Am Heart J
|
2006
|
0.81
|
|
113
|
Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting.
|
Am J Cardiol
|
2002
|
0.81
|
|
114
|
Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group.
|
Am Heart J
|
2009
|
0.80
|
|
115
|
Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites.
|
Am J Cardiol
|
2007
|
0.80
|
|
116
|
The use and limitations of unfractionated heparin.
|
Crit Pathw Cardiol
|
2010
|
0.80
|
|
117
|
Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary intervention.
|
Am J Cardiol
|
2007
|
0.80
|
|
118
|
Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials.
|
Am J Cardiol
|
2003
|
0.80
|
|
119
|
The association between early ventricular arrhythmias, renin-angiotensin-aldosterone system antagonism, and mortality in patients with ST-segment-elevation myocardial infarction: Insights from Global Use of Strategies to Open coronary arteries (GUSTO) V.
|
Am Heart J
|
2009
|
0.80
|
|
120
|
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
|
Circulation
|
2002
|
0.80
|
|
121
|
Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.
|
J Interv Cardiol
|
2003
|
0.80
|
|
122
|
Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy).
|
Am J Cardiol
|
2006
|
0.80
|
|
123
|
Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade: the triad revisited.
|
Circulation
|
2004
|
0.79
|
|
124
|
Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
|
Am Heart J
|
2006
|
0.79
|
|
125
|
Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model.
|
Atherosclerosis
|
2002
|
0.79
|
|
126
|
Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model.
|
Arterioscler Thromb Vasc Biol
|
2002
|
0.78
|
|
127
|
Bivalirudin in PCI: an overview of the REPLACE-2 trial.
|
Semin Thromb Hemost
|
2004
|
0.78
|
|
128
|
Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality.
|
Am J Cardiol
|
2004
|
0.78
|
|
129
|
Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction.
|
Am J Cardiol
|
2008
|
0.78
|
|
130
|
Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials.
|
J Interv Cardiol
|
2003
|
0.78
|
|
131
|
Strategies for the development of new PPAR agonists in diabetes.
|
Eur J Cardiovasc Prev Rehabil
|
2010
|
0.77
|
|
132
|
Should patients on long-term warfarin take aspirin for heart disease?
|
Cleve Clin J Med
|
2008
|
0.77
|
|
133
|
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
|
J Am Coll Cardiol
|
2004
|
0.77
|
|
134
|
Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations.
|
Am J Cardiol
|
2003
|
0.77
|
|
135
|
Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis.
|
Catheter Cardiovasc Interv
|
2010
|
0.77
|
|
136
|
Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions.
|
Am J Cardiol
|
2004
|
0.77
|
|
137
|
Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study.
|
Arterioscler Thromb Vasc Biol
|
2002
|
0.77
|
|
138
|
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.
|
Am J Cardiol
|
2002
|
0.77
|
|
139
|
Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.
|
Catheter Cardiovasc Interv
|
2006
|
0.77
|
|
140
|
Safety profile and bleeding risk of ticagrelor compared with clopidogrel.
|
Expert Opin Drug Saf
|
2012
|
0.76
|
|
141
|
GUSTO V: combination drug treatment of acute myocardial infarction. Global Use of Strategies to Open Occluded Coronary Arteries.
|
Cleve Clin J Med
|
2002
|
0.76
|
|
142
|
Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.
|
Am J Cardiol
|
2006
|
0.76
|
|
143
|
The safety of a bivalirudin-based approach in patients undergoing rotational atherectomy.
|
J Invasive Cardiol
|
2007
|
0.76
|
|
144
|
Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).
|
Am J Cardiol
|
2002
|
0.76
|
|
145
|
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
|
Am Heart J
|
2006
|
0.76
|
|
146
|
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.
|
Eur J Cardiovasc Prev Rehabil
|
2011
|
0.76
|
|
147
|
Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis).
|
Am J Cardiol
|
2007
|
0.76
|
|
148
|
Coupling drug and catheter therapy for myocardial infarction.
|
JAMA
|
2004
|
0.75
|
|
149
|
Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fondaparinux.
|
Evid Based Med
|
2011
|
0.75
|
|
150
|
Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary intervention.
|
Am J Cardiol
|
2006
|
0.75
|
|
151
|
Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis.
|
Clin Cardiol
|
2014
|
0.75
|
|
152
|
Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency.
|
Am J Cardiol
|
2002
|
0.75
|
|
153
|
Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab.
|
Am J Cardiol
|
2002
|
0.75
|
|
154
|
Bleeding complications of unfractionated heparin.
|
Expert Opin Drug Saf
|
2010
|
0.75
|
|
155
|
Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists.
|
Am Heart J
|
2002
|
0.75
|
|
156
|
Direct thrombin inhibitors.
|
Curr Cardiol Rep
|
2005
|
0.75
|
|
157
|
Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
|
EuroIntervention
|
2014
|
0.75
|
|
158
|
Percutaneous coronary revascularization in coronary artery disease: lessons from a single center experience.
|
Catheter Cardiovasc Interv
|
2012
|
0.75
|
|
159
|
Comparison of outcomes of unprotected left main versus multivessel coronary artery interventions.
|
Am J Cardiol
|
2011
|
0.75
|
|
160
|
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial.
|
Coron Artery Dis
|
2013
|
0.75
|
|
161
|
Here and now--state of the art: optimal antithrombotic strategy for percutaneous coronary intervention-panel discussion.
|
J Invasive Cardiol
|
2004
|
0.75
|
|
162
|
Coronary Artery Bypass Surgery Compared With Percutaneous Coronary Intervention for Proximal Left Anterior Descending Artery Treatment in Patients With Acute Coronary Syndrome: Analysis From the ACUITY Trial.
|
J Invasive Cardiol
|
2015
|
0.75
|
|
163
|
Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial.
|
Eur Heart J
|
2005
|
0.75
|
|
164
|
Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition.
|
Am J Cardiol
|
2003
|
0.75
|
|
165
|
Antiplatelet agents in ischemic heart disease.
|
Handb Exp Pharmacol
|
2012
|
0.75
|
|
166
|
Pharmacologic inhibition of platelet function: correlation between in vitro tests of platelet function and clinical outcomes.
|
Am J Cardiovasc Drugs
|
2008
|
0.75
|
|
167
|
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes.
|
Am J Med
|
2003
|
0.75
|
|
168
|
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
|
Am Heart J
|
2004
|
0.75
|
|
169
|
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials.
|
Eur Heart J
|
2004
|
0.75
|